Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A. (Q44053738)

From Wikidata

Jump to navigation Jump to search

scientific article published in April 2004

Language	Label	Description	Also known as
English	Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A.	scientific article published in April 2004

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A. (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Thomas L. Richie

7

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Stephen L. Hoffman

22

object named as

Stephen L Hoffman

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

D. Gray Heppner

9

object named as

D Gray Heppner

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

author name string

Judith E Epstein

1

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Yupin Charoenvit

2

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Kent E Kester

3

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Ruobing Wang

4

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Rhonda Newcomer

5

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Steve Fitzpatrick

6

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Nadia Tornieporth

8

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Chris Ockenhouse

10

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Victoria Majam

11

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Carolyn Holland

12

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Esteban Abot

13

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Harini Ganeshan

14

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Mara Berzins

15

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Trevor Jones

16

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

C Nicole Freydberg

17

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Jennifer Ng

18

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Jon Norman

19

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Daniel J Carucci

20

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Joe Cohen

21

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

language of work or name

0 references

publication date

1 April 2004

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

22

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

13-14

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

1592-1603

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Progress and challenges for malaria vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

The complexity of protective immunity against liver-stage malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 env and rev

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Gene combination raises broad human immunodeficiency virus-specific cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Protection of rhesus macaques against lethal Plasmodium knowlesi malaria by a heterologous DNA priming and poxvirus boosting immunization regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Overcoming immunity to a viral vaccine by DNA priming before vector boosting

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Cancer Gene Therapy Using Plasmid DNA: Purification of DNA for Human Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

An OspA-Based DNA Vaccine Protects Mice against Infection with Borrelia burgdorferi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Plasmodium falciparum: immunogenicity of circumsporozoite protein constructs produced in Escherichia coli.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Identifiers

10.1016/J.VACCINE.2004.01.031

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44053738&oldid=2106065188"